Status:
COMPLETED
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Hormonal therapy is the standard treatment for prostate cancer which has spread to other areas of the body. Despite the high initial response rates to hormonal therapy, the vast majority of men will d...
Eligibility Criteria
Inclusion
- All patients must have a histologic diagnosis of adenocarcinoma of the prostate with evidence of metastases on bone or CT scan. Patients with regional metastases to pelvic lymph nodes (D1 disease) as their only site of metastases will be excluded from this study.
- Patients on androgen suppression therapy at the time of registration must have received less than seven months of therapy (excluding any neoadjuvant hormonal therapy) and must have a decreasing or stable PSA level.
- Patients may not be undergoing concurrent chemotherapy, biologic therapy, or radiation therapy. Prior to radiation therapy must have completed more than 4 weeks prior to registration.
- Patients may not have received prior cytotoxic chemotherapy.
- Patients may not have evidence of brain metastases or untreated spinal cord compression.
Exclusion
Key Trial Info
Start Date :
December 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00151060
Start Date
December 1 1998
End Date
June 1 2006
Last Update
January 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Michigan Comprehensive Cancer
Ann Arbor, Michigan, United States